Editor of Patient Care Online.
Tapinarof Cream 1.0% Effective for Atopic Dermatitis: Daily Dose
Your daily dose of the clinical news you may have missed.
Obesity and Venous Disease: Risk Factors and Key Diagnostic Challenges
Johnson & Johnson Submits sBLA for Approval of Guselkumab for Adults with Ulcerative Colitis
Submission based on results from the phase 3 QUASAR induction study, which showed statistically significant and clinically meaningful improvements in symptoms.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes for up to 1 Year, According to New Data
New research highlights another benefit of COVID-19 vaccination, reported researchers.
Stroke Risk Mitigated by Low Levels of Exercise: Daily Dose
Aspirin Use among Older Adults: Daily Dose
Topline Phase 3 Data Released for Elinzanetant Efficacy for Moderate-to-Severe VMS
The novel dual NK-1,3 receptor antagonist demonstrated statistically significant reduction in the frequency of moderate-to-severe VMS vs placebo.
Underrepresentation of Patients with CKD in CVD Medication Trials: Daily Dose
Obesity and Venous Disease: An Expert Discussion
Shagun Bindlish, MD, board member of the American Diabetes Association, discusses a recent clinical practice statement she coauthored published in the journal Obesity Pillars.
Nirsevimab Effective Against RSV Hospitalization among Infants: Daily Dose
Dyslipidemia in American Indian Youth: Daily Dose
Plastic Debris in Carotid Plaque Linked to CV Events: Daily Dose
Aspirin Use among Older Adults Inconsistent with Current Guidelines, According to New Survey
In a survey of adults aged 50-80 years, 57% of those who reported taking aspirin regularly said they do not have a history of CVD.
In Pregnant Women with T1D, Higher Time-in-Range Improves Maternal, Neonatal Outcomes: Daily Dose
First Issue of Patient Care Online Digital Edition Goes Live
The inaugural digital issue of Patient Care focuses on the antiobesity and type 2 diabetes medications, semaglutide and tirzepatide.
Early Detection of CKD Progression in Primary Care: Daily Dose
Nirsevimab 90% Effective Against RSV Hospitalization among Infants, According to New CDC Data
Findings support current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.
Semaglutide Lowers CKD-Related Events in Persons with T2D, CKD: Daily Dose
New Data Show High Prevalence of Dyslipidemia in American Indian Youth
Few participants with dyslipidemia received lipid-lowering medications despite high prevalence, reported authors of the Strong Family Heart Study.
Migraine, Persistent VMS Tied to Higher Risk of CVD, Stroke: Daily Dose
Plastic Debris Detected in Carotid Plaque Linked to Higher Risk for MI, Stroke, Death
Patients who had microplastics and nanoplastics in their carotid plaque were at more than a fourfold risk for MI, stroke, or death compared to those who did not, according to a new study.
Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose
Semaglutide Shows Potential for Significant CVD Prevention: Daily Dose
CDC: Persons with COVID-19, Flu, RSV, Other Respiratory Viruses No Longer Have to Isolate for 5 Days
The updated guidelines reflect the progress made in protecting against severe illness from COVID-19, said CDC Director Mandy Cohen, MD, MPH.
Cannabis Use Associated with Higher Risk of MI, Stroke: Daily Dose
Phase 3 Findings on Neffy for Pediatric Patients with Severe Allergies: A Conversation with Motohiro Ebisawa, MD, PhD
Dr Ebisawa details the findings he recently presented at the 2024 AAAAI annual meeting, including adverse events and next steps for the study.
Atogepant Safe, Effective in Treatment-Resistant Episodic Migraine: Daily Dose
Migraine and Persistent Vasomotor Symptoms Linked to Higher Risk of CVD, Stroke in Analysis of CARDIA Study
Women with migraine and persistent VMS faced double the risk of CVD and triple the risk of stroke, reported researchers.
Women with IBD at Risk for Reduced Fertility: Daily Dose
State of US Mental Health: Happiest Cities in 2024
Which city has the highest depression rate? Or the fewest work hours? Find the answers and more insights from a nationwide analysis, here.